on behalf of the iHIVARNA consortium Correction to: Trials
During the revision process of this paper, it became apparent that the study product iHIVARNA-01 contains an error in that the RNA sequence contained by mistake a second start codon in front of the HTI immunogen coding sequence. This error is likely to influence the expression of the HTI protein, from the mRNA vaccine. Even though the degree to which this impacted the expression of HTI remains unclear, the results of the preclinical trial show that there is sufficient expression for the induction of an immunogen-specific T-cell response in mice.
Corrected end note:
After completing the phase I and phase II trial, it became apparent that the study product iHIVARNA-01 contains an error in that the RNA sequence contained by mistake a second start codon upstream of the HTI immunogen coding sequence. This error is likely to influence the expression of the HTI protein, from the mRNA vaccine. The degree to which this impacted the expression of HTI remains unclear. The results of the preclinical study showed an induction of an immunogen specific T cell response in mice which could not be correlated with known HTI expression as the expression level of the HTI peptide has not been assessed. Similarly, in the clinical studies, the level of expression of the immunogen was not quantified.
